PT -期刊文章盟Tejaswi Kandula AU -米歇尔·法勒AU -马修·基尔南AU -大卫Mizrahi AU -凯特·凯里盟阿伦Krishnan TI - AU -理查德科恩盟苏珊娜公园长期结果和化疗引起的周围神经病变的危险因素在儿童癌症幸存者(S46.006) DP - 2017年4月18日TA -神经病学PG - S46.006 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/S46.006.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/S46.006.首页full所以Neurology2017 4月18日;88 AB -目的:本研究旨在评估流行,影响和化疗引起的周围神经病变的危险因素(CIPN)长期儿童癌症幸存者(CCS)。背景:神经毒性化疗常用于治疗儿童癌症和CIPN发病率在CCS的可能是一个重要原因,有助于减少身体功能和限制参与日常活动。设计/方法:综合神经毒性的评估是在CCS完成铂化疗或基于长春花生物碱在5年前,包括临床、功能、生活质量和神经生理学参数包括常规神经传导研究和小说神经兴奋性研究。结果:神经毒性评估进行7-47岁110名参与者,接受化疗的平均年龄为5.8±0.4岁和11.2±0.7年前完成治疗。33%的患者临床和/或周围神经病变的神经生理学证据。总的来说,降低CCS示范感官振幅相比年龄组(平均差−6.3μv;95% ci 9.6−−3.0μv;p = 0.0003),表明影响轴突储备。参与者对待白金代理(p = 0.008)或双神经毒性化疗是最受影响的(p = 0.01)。有持续的异常功能感觉神经的兴奋性属性在参与者之前顺铂治疗(术中,0.05)。 Clinical functional parameters of manual dexterity (44.5th percentile, 95%CI 36.1, 52.9%), balance (49th percentile, 95%CI 38.9, 59%) and co-ordination (55.9th percentile, 95%CI 46.9,65%) were relatively preserved compared to the normal population.Conclusions: CIPN produces significant long term morbidity in CCS. Clinical and neurophysiological abnormalities in CCS are consistent with global axonal loss, which in conjunction with altered functional axonal properties may predispose to age related degenerative change. Exposure to platinum or dual neurotoxic chemotherapy are risk factors for long term neuropathy. Relative preservation of clinical function suggests a window of opportunity for physical therapy which may preserve long term function.Study Supported by:This work was supported by the National Health and Medical Research Council (APP1114801), the Royal Australasian College of Physicians and the Cancer Institute of the New South Wales (grant number 14/TPG/1-05).Disclosure: Dr. Kandula has nothing to disclose. Dr. Farrar has nothing to disclose. Dr. Kiernan has received personal compensation in an editorial capacity for Journal of Neurology, Neurosurgery and Psychiatry. Dr. Mizrahi has nothing to disclose. Dr. Carey has nothing to disclose. Dr. Krishnan has received personal compensation for activities with Biogen Idec as a member of an advisory board. Dr. Cohn has nothing to disclose. Dr. Park has nothing to disclose.